Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-03

Clinical Trial Update: The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating SPD465 for adults with ADHD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPD465

Snippet

Sponsor: Shire | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 2 | Status: COMPLETED